Y101D

PD-L1/TGF-β bispecific antibody · Wuhan YZY Biopharma Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Y101D, covering 2025-07-20 to 2025-07-20. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors [Phase 1]

See pricing